Top

Published in:

01-12-2019 | Human Immunodeficiency Virus | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editor)

Onychomycosis in Patients Living with HIV/AIDS

Author: Gabriela Moreno-Coutiño

Published in: Current Fungal Infection Reports | Issue 4/2019

Abstract

Purpose of Review

As both onychomycosis and HIV/AIDS are frequently encountered, we aimed to make a review of the existent information to this moment, including classification, evaluation and treatment.

Recent Findings

The new description of dermatophytes will surely originate changes in the classification and probably in the therapeutic approach. Also, we must be watchful for the modifications that may develop in this pathology with the newer antirretrovirals which are in constant evolution and could modify the patients’ response to dermatophytosis.

Summary

At this moment, we know that onychomycosis is very common in patients living with HIV.

Although they present similar clinical patterns and aetiological agents to the general population, we must focus in the many differences they present to further understand the physiopathology in the HIV setting.

We are still searching for the ideal antimycotic and the full understanding of the pathogenesis of the infection in this particular group of patients.

https://www.who.int/es/news-room/fact-sheets/detail/hiv-aids. 10-04-2019.

De Hoog GS, Dukik K, Monod M, Packeu A, Stubbe D, Hendrickx M, et al. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. Mycopathol. 2017;182:5–31. https://doi.org/10.1007/s11046-016-0073-9.CrossRef

Hay R, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011;65:1219–27. https://doi.org/10.1016/j.jaad.2010.09.730.CrossRefPubMed

• Baran R, Faergemann J, Hay RJ. Superficial White onychomycosis-a syndrome with different fungal causes and paths of infection. J Am Acad Dermatol. 2007;57:879–82. https://doi.org/10.1016/j.jaad.2007.05.026. This article proposes new infection routes for onychomycosis. CrossRefPubMed

Sergeev AY, Gupta AK, Sergeev YV. The scoring clinical index for onychomycosis (SCIO index). Skin Therapy Lett. 2002;1:6–7.

Carney C, Tosti A, Daniel R, Scher R, Rich P, DeCoster J, et al. A new classification system for grading the severity of onychomycosis. Arch Dermatol. 2011;147:1277–82. https://doi.org/10.1001/archdermatol.2011.267.CrossRefPubMed

Dompmartin D, Dompmartin A, Deluol AM, Grosshans E, Coulaud JP. Onychomycosis and AIDS. Int J Dermatol. 1990;29:337–9.CrossRef

•• Moreno-Coutiño G, Arenas R, Reyes-Terán G. Improvement of onychomycosis after initiation of combined antiretroviral therapy. Int J Dermatol. 2013;52:311–3. https://doi.org/10.1111/j.1365-4632.2011.05346.x. New observations. CrossRefPubMed

Gómez-Moyano E, Crespo-Erchiga V. HIV infection manifesting as proximal White onychomycosis. N Engl J Med. 2017;377(18):e26. https://doi.org/10.1056/NEJMicm1703082.CrossRefPubMed

10.

Daniel CR III, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus. J Am Acad Dermatol. 1992;27:93–7.CrossRef

11.

• Ruíz-López P, Moreno-Coutiño G, Fernandez-Martínez R, Espinoza-Hernández J, Rodríguez Zulueta P, Reyes-Terán G. Evaluation of improvement of onychomycosis in HIV infected patients after initiation of combined antiretroviral therapy without antifungal treatment. Mycoses. 2015;58:516–21. https://doi.org/10.1111/myc.12350. This article highlights the different characteristics of onychomycosis in HIV population and their particular evolution. CrossRefPubMed

12.

Jiménez-González C, Mata-Marin JA, Arroyo-Anduiza CI, Ascencio-Montiel IJ, Fuentes-Allen JL, Gaytán-Martínez J. Prevalence and aetiology of onychomycosis in the HIV infected population. Eur J Dermatol. 2013;23:378–81. https://doi.org/10.1684/ejd.2013.2015.CrossRefPubMed

13.

Moreno-Coutiño G, Reyes-Terán G. Dermatosis en pacientes con VIH/SIDA en el Centro de Investigación de Enfermedades Infecciosas. Salud Pública Mex. 2015;57:486–7.PubMed

14.

• Vasudevan B, Sagar A, Bahal A, Mohanty AP. Cutaneous manifestations of HIV- a detailed study of morphological variants, markers of advanced disease, and the changing spectrum. Med J Armed Forces India. 2012;68:20–7. https://doi.org/10.1016/S0377-1237(11)60122-6. Good clinical review. CrossRefPubMedPubMedCentral

15.

Sánchez-Moreno EC, Marioni-Manriquez S, Fernández Martínez RF, Moreno-Coutiño G. Accelerated nail growth rate in HIV patients. Int J Dermatol. 2017;56:524–6. https://doi.org/10.1111/ijd.13498.CrossRefPubMed

16.

Sunny N, Nair SP, Justus L, Beena A. Total dystrophic onychomycosis caused by Talaromyces marneffei in a patient with acquired immunodeficiency syndrome on combined anti-retroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84:87–90. https://doi.org/10.4103/ijdvl.IJDVL_971_16.CrossRefPubMed

17.

Kaplan MH, Sadick N, McNutt S, Meltzer M, Sarngadharan, Pahwa S. Dermatologic findings and manifestations of acquired immunodeficiency síndrome (AIDS). J Am Acad Dermatol. 1987;16:485–506.CrossRef

18.

• Velasquez-Agudelo V, Cardona-Arias JA. Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis. BMC Infect Dis. 2017;17:166. https://doi.org/10.1186/s12879-017-2258-3. Good review. CrossRefPubMedPubMedCentral

19.

Jeelani S, Ahmed QM, Lanker AM, Hassan I, Jeelani N, Fazili T. Histopathological examination of nail clippings using PAS staining (HPE-PAS): gold standard in diagnosis of onychomycosis. Mycoses. 2015;58:27–32. https://doi.org/10.1111/myc.12251.CrossRefPubMed

20.

Hajar T, Fernández-Martínez R, Moreno-Coutiño G, Vásquez del Mercado E, Arenas R. Modified PAS stain: a new diagnostic method for onychomycosis. Rev Iberoam Micol. 2016;33:34–7. https://doi.org/10.1016/j.riam.2014.10.002.CrossRefPubMed

21.

Mayer E, Izhak OB, Bergman R. Histopathological periodic acid-schiff stains of nail clippings as a second-line diagnostic tool in onychomycosis. Am J Dermatopathol. 2012;34:270–3. https://doi.org/10.1097/DAD.0b013e318234cc49.CrossRefPubMed

22.

Nagar R, Nayak CS, Deshpande S, Gadkari RP, Shastri J. Subungual hyperkeratosis nail biopsy: a better diagnostic tool for onychomycosis. India J Dermatol Venereol Leprol. 2012;78:620–4. https://doi.org/10.4103/0378-6323.100579.CrossRef

23.

Ghannoum M, Mukherjee P, Isham N, Markinson B, Del Rosso J, Luis L. Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis. Int J Dermatol. 2018;57:131–8. https://doi.org/10.1111/ijd.13690.CrossRefPubMed

24.

Nargis T, Pinto M, Shenoy MM, Hedge S. Dermoscopic features of distal lateral subungual onychomycosis. Indian Dermatol Online J. 2018;9:16–9. https://doi.org/10.4103/idoj.IDOJ_40_17.CrossRefPubMedPubMedCentral

25.

Bet DL, dos Reis AL, Di Chiacchio N, Belda W Jr. Dermoscopy and onychomycosis: guided nail abrasión for mycological samples. An Bras Dermatol. 2015;90:904–6. https://doi.org/10.1590/abd1806-4841.20154615.CrossRefPubMedPubMedCentral

26.

De la Fuente GA, Ocampo-Candiani J. Melanoma cutáneo. Gac Med Mex. 2010;146:126–35.

27.

Riahi RR, Cohen PR, Goldberg LH. Subungual amelanotic melanoma masquerading as onychomycosis. Cureus. 2018;10(3):e2307. https://doi.org/10.7759/cureus.2307.CrossRefPubMedPubMedCentral

28.

Zhang L, Xu H, Shj Y, Tao Y, Li X. An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Mycoses. 2018. https://doi.org/10.1111/myc.12799.CrossRef

29.

• Kreijkamp-Kaspers S, Hawke KL, van Driel ML. Oral medications to treat toenail fungal infection. JAMA. 2018;319:397–8. https://doi.org/10.1001/jama.2017.20160. Good review of therapies. CrossRefPubMed

30.

Snell M, Klebert M, Önen N, Hubert S. A novel treatment for onychomycosis in people living with HIV infection: Vicks VapoRub™ is effective and safe. J Assoc Nurses AIDS Care. 2016;27:109–13. https://doi.org/10.1016/j.jana.2015.10.004.CrossRefPubMed

31.

• Rizi K, Mohammed IK, Xu K, Kinloch AJ, Charalambides MN, Murdan S. A systemic approach to the formulation of anti-onychomycotic nail patches. Eur J Pharm Biopharm. 2018;127:355–65. https://doi.org/10.1016/j.ejpb.2018.02.032. Interesting proposal for new therapy development. CrossRefPubMed

32.

Veiga FF, Gadelha MC, da Silva MRT, Costa MI, Kischkel B, de Castro-Hoshino LV, et al. Propolis exrtract for onychomycosis topical treatment: from bench to clinic. Front Microbiol. 2018;9:779. https://doi.org/10.3389/fmicb.2018.00779.CrossRefPubMedPubMedCentral

33.

Park KY, Suh JH, Kim BJ, Kim MN, Hong CK. Randomized clinical trial to evaluate the efficacy and safety of combination therapy with short pulsed 1,064 nm neodinium-doped yttrium aluminium garnet laser and amorolfine nail lacquer for onychomycosis. Ann Dermatol. 2017;29:699–705. https://doi.org/10.5021/ad.2017.29.6.699.CrossRefPubMedPubMedCentral

34.

• Sonthalia S, Jakhar D, Yadav P, Kaur I. Chemical peeling as an innovative treatment alternative to oral antifungals for onychomycosis in special circumstances. Skin Appendage Disord. 2019;5:181–5. https://doi.org/10.1159/000495152. Interesting proposal for new therapy modalities. CrossRefPubMed

Title: Onychomycosis in Patients Living with HIV/AIDS
Author: Gabriela Moreno-Coutiño
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Human Immunodeficiency Virus
Nail Disease
Acquired Immune Deficiency Syndrome
Onychomycosis
Published in: Current Fungal Infection Reports / Issue 4/2019
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-019-00348-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

The Use of Whole Genome and Next-Generation Sequencing in the Diagnosis of Invasive Fungal Disease

Pityriasis Versicolor in Children and Adolescents: an Update

Update of Vulvovaginal Candidiasis in Pregnant and Non-pregnant Patients

Genetic Variation and Fungal Infection Risk: State of the Art

Congenital Cutaneous Candidiasis: Uncommon Entity or Underdiagnosed?

From Culture to Fungal Biomarkers: the Diagnostic Route of Fungal Infections in Children with Primary Immunodeficiencies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials